Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Jazz Pharmaceuticals plc
Bear Case (25th pct.)
17.9% vs price
Base Case (Median)
59.5% vs price
Bull Case (75th pct.)
90.9% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| PE Comparable | $328.32 | 36.4% | Medium (25%) |
| Growth Trajectory DCF | $518.95 | 115.6% | Medium (20%) |
| Graham Number | $149.98 | -37.7% | Medium (40%) |
| EV/FCF | $439.73 | 82.7% | Medium (20%) |
Based on 4 out of 7 methods, JAZZ appears undervalued at the current price of $240.74. The base case fair value of $384.03 implies 59.5% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.